According to the KEGG pathway analysis, the high-risk group did not have an enrichment in the signaling pathway, while chronic myeloid leukemia, dorsoventral axis formation, drug metabolism cytochrome p450 and the VEGF signaling pathway were enriched in the low-risk group (Figure 7C). The gene discussed is VEGFA; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.